+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

The World Market for Molecular Diagnostics Tests, 10th Edition

  • ID: 5367417
  • Report
  • June 2021
  • Region: Global
  • 335 Pages
  • Kalorama Information

FEATURED COMPANIES

  • Abbott Diagnostics
  • Bd Life Sciences
  • Bioneer
  • Exact Sciences Corp.
  • Myriad Genetics, Inc.
  • Recent Acquisitions
  • MORE
Molecular diagnostics is a fast evolving and dynamic field and is the fastest growing segment within the in vitro diagnostics (IVD) market. It has become an indispensable tool in clinical medicine that touches all aspects of healthcare including treatment decisions in terms of identifying antimicrobial resistant (AMR) infections at the earliest, companion diagnostics assisting in the evaluation of suitability of various cancer treatment options, pharmacokinetics or patient metabolism of drugs for HIV, psychiatric conditions or blood thinners; cancer prognosis and therapy, organ matching, blood safety, and the diagnosis of latent and neonatal conditions.

The World Molecular Diagnostics Market, 10th Edition, examines the global market as well as markets by region, including:

  • Global Markets for Molecular Diagnostics by Application Segments (2021-2026) (Infectious Diseases, Blood Screening, Histology, Cancer Assays, Transplant, Inherited Diseases, Total) ($, Million)
  • Global Markets for Molecular Diagnostics by Technology Segments (2021-2026) (PCR, iNAAT, Microarrays, ISH, NGS, Other, Total) ($, Million)
  • North American Markets for Molecular Diagnostics (2021-2026) (Infectious Diseases, Blood Screening, Histology, Cancer Assays, Transplant, Inherited Diseases, Total) ($, Million)
  • European Markets for Molecular Diagnostics (2021-2026) (Infectious Diseases, Blood Screening, Histology, Cancer Assays, Transplant, Inherited Diseases, Total) ($, Million)
  • Asia Pacific Markets for Molecular Diagnostics (2021-2026) (Infectious Diseases, Blood Screening, Histology, Cancer Assays, Transplant , Inherited Diseases, Total) ($, Million)
Detection of active and latent patient infections by targeting genetic sequences specific to pathogens is the approach used in molecular infectious disease tests. Clinical molecular tests available for infectious disease testing offer a combination of high sensitivity, specificity and low turnaround time advantages.

This has powered this segment for high market growth over other major diagnostic platforms commonly used for infectious disease testing such as immunoassay and ID/AST. Molecular detection platforms are increasingly being recognized for the improved sensitivity and specificity they can offer, even though they are more expensive.

The report offers global analysis of the molecular infectious disease diagnostics segment, as well as analysis of subsegments that include CT/NG, HPV, hepatitis, HIV, HAIs, respiratory diseases, and tuberculosis:

  • Global Molecular Infectious Disease Diagnostics Markets (2021-2026), By Infection (Hepatitis, HIV, HAIs/Sepsis, HPV, CT/NG, Respiratory diseases, Mycobacteria/TB, Other, Total) ($, Million)
  • Global Molecular Infectious Disease Diagnostics Markets, by Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
  • Global Molecular HPV Testing Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
  • Global Molecular CT/NG Testing Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
  • Global Molecular Hepatitis Testing Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
  • Global Molecular HIV Testing Markets, By Region (North America, Europe, APAC, RoW, Total) (2021-2026) ($, Million)
  • Global Molecular HAIs/Sepsis Testing Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
  • Global Molecular Respiratory Diseases Testing Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
  • Global Molecular Mycobacteria/TB Testing Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
  • As a result of concerted efforts to make blood product transfusions safer, there is an increase in antigen testing by nucleic acid test (NAT) screening to test for common pathogens. Developing countries are replacing immunoassays by molecular tests, especially for HIV, hepatitis, etc.

World Molecular Diagnostics Market covers the markets for molecular blood screening diagnostics, outlining the blood testing market by geography:

  • Global Molecular Blood Screening Diagnostics Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
Molecular histology, which predominantly consists of ISH tests, captures several different areas of testing including molecular cytogenetics or study of chromosomes, related techniques for the detection of pre- and post-natal genetic disorders, cancer testing, and the detection of pathogens or pathogenic activity from tissues and blood cultures. Various sub-segments within the ISH segment of molecular histology market include FISH, CISH, Rapid ISH (RISH), etc. CISH for RNA markers is increasingly used in drug development and companion diagnostics.

The report analyzes key molecular histology segments:

  • Global Molecular Histology and Cytology Diagnostics Markets by Application (2021-2026) (Cancer, Inherited diseases, Infectious/Other, Total) ($, Million)
  • Global Molecular Histology and Cytology Diagnostics Markets, by Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
  • Global Molecular Histology Diagnostics Markets, by Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
This report reviews the current makeup of the molecular diagnostics market in cancer, including its notable products and geographical segmentation. The report also reviews expected developments, such as technology and product introduction. The current market is largely composed of tissue-based tests, companion assays, and tests for the prognosis and diagnosis of specific cancer types. Some of the most significant developments in this field may have an impact in shaping cancer diagnostics and treatment management.

The report examines the markets for molecular cancer diagnostics, outlining the global market by geography:

  • Global Molecular Cancer Diagnostics Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
The molecular transplant diagnostics space is a competitive market with many companies offering PCR-based and bead-array-based test kits based on the HLA genes that have been characterized. The demand for NGS has been growing in the segment. An HLA test requires that some six genes are screened in parallel, with each displaying about 100 important (known) local variants. This requirement lends itself to technologies such as microarrays and sequencing that can screen for many targets.

The report outlines the markets for molecular transplant diagnostics by geography:

  • Global Molecular Transplant Diagnostics Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
The detection of single nucleotide polymorphisms (SNPs) or gene variants from tissue, blood, urine and saliva samples can be used to diagnose inherited diseases and genetic disorders as well as determine the risk of disease manifestation or progression. One of the major challenges facing molecular tests for gene based inherited diseases is getting stakeholders including payers, physicians, researchers and regulators to work together to close the gap between research and clinical applicability.

World Molecular Diagnostics Market analyzes the developments in most significant markets within molecular inherited disease diagnostics and provides the following market data:

  • Global Molecular Inherited Diseases Diagnostics Markets, By Disease Segments (2021-2026) (Thrombophilia [SNP tests] & Coagulation Markers, NIPT, Others, Total) ($, Million)
  • Global Molecular Inherited Diseases Diagnostics Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
In addition to reviewing recent industry and market developments, as well as examining key market trends that are influencing the market landscape, the report looks at the molecular diagnostics industry players.

The following companies are profiled:

  • Abbott Diagnostics
  • Advanced Cell Diagnostics (Biotechne)
  • Agilent Technologies
  • Amoy Diagnostics
  • Applied Spectral Imaging
  • Becton, Dickinson & Co. (BD)
  • Beijing Genomics Institute (BGI)
  • Berry Genomics
  • bioMe´rieux
  • Bio-Rad Laboratories
  • CareDx, Inc.
  • Danaher (Cepheid and Leica Biosystems)
  • Eiken Chemical
  • GenMark Diagnostics
  • Genotypic Technology Pvt. Ltd.
  • Grifols, S.A
  • Illumina
  • Immucor, Inc.
  • Meridian Bioscience Inc
  • Molbio Diagnostics Pvt. Ltd.
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Quidel Corporation
  • Roche Diagnostics
  • Thermo Fisher Scientific Inc.
  • Vela Diagnostics
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Diagnostics
  • Bd Life Sciences
  • Bioneer
  • Exact Sciences Corp.
  • Myriad Genetics, Inc.
  • Recent Acquisitions
  • MORE

CHAPTER 1: EXECUTIVE SUMMARY  

  • MOLECULAR DIAGNOSTICS IN THE SPOTLIGHT
    • Figure 1-1: Molecular Diagnostics Market (w COVID-19 and w/out COVID-19, 2021 ($B)  
  • Hundreds of PCR Tests on the Market, U.S. Labs Settle on a Few 
  • COVID-19 Market
    • Table 1-1: Table 1-1: COVID-19 Molecular Testing Market, First Half-Year 2020, Full Year 2020, and Q 2021 ($M)  
    • Figure 1-2: Estimated COVID-19 Molecular Diagnostic Revenue, Q1 2020-Q1 2021  
  • EMERGING TRENDS 
  • Automation 
  • Molecular Point of Care  
    • Table 1-2: Market-Available Molecular POC Diagnostic Platforms 
  • Next-Generation Sequencing on the Rise
  • LDT Regulation and COVID-19
  • Reimbursement Environment  
  • Thermo and Qiagen Merger  
    • Table 1-3: Complementary diagnostic products offered by Thermo Fisher, Qiagen 
  • CRISPR, Sequencing and COVID-19 
  • THE GLOBAL MOLECULAR DIAGNOSTICS MARKET IN THE ERA OF COVID-19 
    • Table 1-4: Non-COVID-19 Molecular Diagnostics Market, 2020-2026 ($M) 

CHAPTER 2: COVID-19 MOLECULAR DIAGNOSTIC MARKET ANALYSIS 

  • MAJOR IVD PLAYERS SEE BRISK COVID-19 TEST SALES
    • Table 2-1: COVID-19 Molecular Detection Tests from Major Suppliers
    • Figure 2-1: COVID-19 Molecular Diagnostics Monthly Volume 
    • Figure 2-2: COVID-19 Molecular Diagnostics Monthly Test Volume 
    • Table 2-2a: COVID-19 Molecular Diagnostics Revenues by Region Estimated: North America, Europe, APAC, ROW, LATAM, World, Q1 2020-Q1 2021 (in $) 
    • Table 2-2b: COVID-19 Molecular Diagnostics Shares by Region Estimated: North America, Europe, APAC, ROW, LATAM, World, 2020-Q1 2021 (%) 
    • Figure 2-3: COVID-19 Molecular Diagnostics Estimated Revenue by Region
    • Figure 2-4: COVID-19 Revenue Shares by Region  
  • NORTH AMERICA
    • Table 2-3: COVID-19 Tests, North America (early June 2021) 
    • Figure 2-5: USA – New Cases per Day 
    • Figure 2-6: USA Daily Testing Volume 
    • Figure 2-7: Canada – New Cases per Day  
    • Figure 2-8: Canada Daily Testing Volume  
  • EUROPE
    • Table 2-4: COVID Tests, Europe (early June 2021)
    • Figure 2-9: Italy – New Cases per Day 
    • Figure 2-10: Italy Daily Testing Volume 
    • Figure 2-11: Russia – New Cases per Day  
    • Figure 2-12: Russia Daily Testing Volume  
  • APAC..
    • Table 2-5: COVID Tests APAC Region (early June 2021)
    • Figure 2-13: India – New Cases per Day
    • Figure 2-14: India Daily Testing Volume
    • Figure 2-15: Australia – New Cases per Day  
    • Figure 2-16: Australia Daily Testing Volume  
  • LATIN AMERICA  
    • Table 2-6: Latin America COVID Testing (early June 2021) 
    • Figure 2-17: Colombia – New Cases per day 
    • Figure 2-18: Colombia Daily Testing Volume 
    • Figure 2-19: Chile – New Cases per Day
    • Figure 2-20: Chile Daily Testing Volume
  • REST-OF-WORLD
    • Table 2-7: Rest of World Testing (early June 2021) 
    • Figure 2-21: Turkey – New Cases per Day 
    • Figure 2-22: Turkey Daily Testing Volume 
    • Figure 2-23: South Africa – New Cases per Day
    • Figure 2-24: South Africa Daily Testing Volume
  • COVID TESTING MARKET COMPUTATION METHODOLOGY
  • TEST VENDORS 
    • Table 2-8: Other PCR Tests Products on the Market 
  • TESTING TRENDS, RECOMMENDATIONS, CONSENSUS TAKING SHAPE

CHAPTER 3: MARKETS FOR OTHER MOLECULAR DIAGNOSTIC TESTS  

    • Table 3-1a: Molecular Diagnostic Market, 2021 and 2026 by Category ($M) 
    • Table 3-1b: Molecular Diagnostic (non-COVID) Market, by Region 2021 ($M) 
    • Figure 3-1: Molecular Diagnostics (non-COVID) Market by Region 2021 ($M) 
  • RECENT PRODUCT INTRODUCTIONS AND REGULATORY APPROVALS  
    • Table 3-2: Recent Product Introduction
    • Table 3-3: Recent Regulatory Approvals and Related Announcements
  • INFECTIOUS DISEASES  
  • Respiratory Diseases: COVID-19 Impact.. 
  • Mycobacteria/Tuberculosis: Market and COVID-19 Impact 
  • Product Developments  
  • Hospital-Acquired Infections (HAIs) : Market and COVID-19 Impact
  • COVID as a hospital infection?  
  • Vendors
  • Sexually Transmitted Infections: Market and COVID-19 Impact 
  • Increased Vendor Activity in Molecular Trichomoniasis vaginalis (TV) 
  • Hepatitis: COVID-19 Impact  
  • New HCV Screening Guidelines 
    • Table 3-4: Selected Molecular Hepatitis Tests  
  • HIV Market and COVID-19 Impact
    • Table 3-5: Selected Molecular Test Products for HIV
  • NAT BLOOD SCREENING  
  • COVID-19 Impact 
  • Other Trends 
  • Declining Blood Transfusions in Developed Markets
  • MOLECULAR HISTOLOGY AND CYTOLOGY DIAGNOSTICS 
  • COVID-19 Impact 
  • HPV 
  • Eliminating HPV Threat? Lancet Public Health Study
  • COVID-19 Impact 
  • Product Developments  
  • MARKETS FOR MOLECULAR CANCER DIAGNOSTICS 
  • Cancer Molecular Blood Markers - COVID-19 Impact 
  • Other Trends 
  • Liquid Biopsy 
  • MOLECULAR TRANSPLANT DIAGNOSTICS 
  • COVID-19 
    • Table 3-6: Selected Innovations in the Field of Molecular Transplant Diagnostics 
  • MOLECULAR INHERITED DISEASES DIAGNOSTICS 
  • Inherited Diseases - COVID-19 Impact  
  • Thrombophilia and Coagulation Markers 
  • Non-Invasive Prenatal Testing (NIPT) 
  • Promising NIPT Studies 
  • Inherited Disease Tests.. 
  • MOLECULAR DIAGNOSTICS MARKET DEALS, COLLABORATIONS, ACQUISITIONS 
    • Table 3-7: Selected Deals

CHAPTER 4: TRENDS TO WATCH - SEQUENCING, CRISPR, AUTOMATION SEQUENCING 

  • Avoiding New Waves of Infection 
  • COVID and NGS 
  • NGS and Inherited Disease  
  • NGS and Companion Diagnostics
    • Table 4-1: Selected Clinical NGS Platforms in the Market 
  • Outlook For NGS in Molecular Diagnostics 
    • Figure 4-1: Percent of the MDX Market Revenues for Tests Using NGS 2020 and 2025 
  • Evolving Informatics Solutions in Clinical Sequencing 
  • Sample Preparation and Quality Control
  • LAB AUTOMATION AND MOLECULAR DIAGNOSTICS 
    • Table 4-2: Selected Automated Molecular Test Instrument Platforms 
    • Table 4-3: Selected FDA Declared EUA Tests
  • CRISPR AND MOLECULAR DIAGNOSTICS  
  • CRISPR and COVID-19  
    • Table 4-4: CRISPR Innovations 

CHAPTER 5: COMPANY PROFILES 

  • ABBOTT DIAGNOSTICS 
  • Company Overview 
  • Financial Review  
    • Table 5-1: Abbott Diagnostics' Recent Revenue History ($M), 2015-2020 
    • Figure 5-1a: Abbott Diagnostics' Molecular Diagnostics Revenue History ($M), 2016- Q1 2021
    • Figure 5-1b: Abbott Diagnostics' Molecular Diagnostics Revenue History ($M), 2016- Q1 2021 
  • COVID-19 
  • FDA approval of ALK Break Apart FISH Probe Kit
  • Alinity s System 
  • WHO prequalification (PQ) approval of viral load test 
  • ADVANCED CELL DIAGNOSTICS (BIO-TECHNE)
  • Company Overview 
  • AGENA BIOSCIENCE 
  • Company Overview 
  • AGENDIA BV 
  • Company Overview 
  • AGILENT TECHNOLOGIES (INCL. DAKO) 
  • Company Overview 
  • Financial Review  
    • Table 5-2: Agilent Technologies' Recent Revenue History ($ millions)
    • Figure 5-2: Diagnostics and Genomics Revenue ($M), 2016- Q1 2021 
  • AIDIAN OY  
  • Company Overview 
  • ALTONA DIAGNOSTICS 
  • Company Overview 
  • AMOY DIAGNOSTICS 
  • Company Overview 
  • APPLIED SPECTRAL IMAGING 
  • Company Overview 
  • ARUP LABORATORIES 
  • Company Overview 
    • Table 5-3: ARUP Labs' Recent Revenue History ($ millions)
  • ASURAGEN INC. (BIO-TECHNE) 
  • Company Overview 
  • BECTON, DICKINSON & CO. (BD)
  • Company Overview 
  • Business Segments  
  • BD Medical. 
  • BD Life Sciences 
  • BD Interventional
  • Recent Acquisitions 
  • TVA Medical, Inc. 
  • C. R. Bard, Inc. 
  • CareFusion Corporation  
  • Recent Divestitures 
  • Advanced Bio-processing
  • Respiratory Solutions and Vyaire Medical 
  • Leading Position in the Flow Cytometry Market 
  • Revenue and Growth 
    • Figure 5-3: BD Quarterly Revenues ($M)
  • Molecular Diagnostics Focus 
  • BEIJING GENOMICS INSTITUTE (BGI)
  • Company Overview 
  • Complete Genomics
  • Sanger Sequencing  
  • BERRY GENOMICS 
  • Company Overview 
  • BINX HEALTH
  • Company Overview 
  • BIO-RAD LABORATORIES, INC.
  • Company Overview 
  • Recent Revenue History  
    • Table 5-4: Bio-Rad Revenue History ($M) 
  • BIOCARTIS 
  • Company Overview 
  • Financial Review  
    • Table 5-5: Biocartis' Recent Revenue History ($ millions) 
  • BIODESIX
  • Company Overview 
  • BIOMEME, INC 
  • Company Overview 
  • Company Overview 
    • Table 5-6: bioMérieux Revenue History  
    • Figure 5-4: bioMérieux’s Molecular Biology and Microbiology Segments  
  • Molecular
  • BIONEER 
  • Company Overview 
  • AccuPower COVID-19 Real-Time RT-PCR Kit 
  • CAREDX, INC.  
  • Company Overview 
    • Figure 5-5: CareDx Recent Revenues  
  • AlloMap Tests  
  • AlloSure Tests  
  • Products Offered by CareDx
  • CREDO BIOSCIENCE 
  • Company Overview 
  • CTK BIOTECH  
  • Company Overview 
  • DANAHER (CEPHEID AND LEICA BIOSYSTEMS)
  • Company Overview 
  • Life Sciences Business  
  • Diagnostics Business 
  • Cepheid 
  • Leica Biosystems 
  • Danaher’s 2019 Performance and 2020 Expectations
    • Figure 5-6: Danaher Recent Revenues
  • DIASORIN 
  • Company Overview 
  • EIKEN CHEMICAL  
  • Company Overview 
  • EXACT SCIENCES CORP.  
  • Company Overview 
  • FLUIDIGM CORPORATION 
  • Company Overview 
  • GENMARK DIAGNOSTICS (ROCHE) 
  • Company Overview 
    • Figure 5-7: GenMark Recent Revenues 
  • GENOTYPIC TECHNOLOGY PVT. LTD.
  • Company Overview 
  • GREINER BIO-ONE GMBH  
  • Company Overview 
  • GRIFOLS, S. A  
  • Company Overview 
  • Molecular Immunohematology and Specialty Testing Products 
  • NAT Blood Screening 
  • HOLOGIC, INC. 
  • Company Overview 
    • Figure 5-8:  Hologic Recent Revenues 
    • Table 5-7: Hologic's Recent Revenue History ($ millions) 
  • ILLUMINA, INC.
  • Company Overview 
    • Table 5-8: Illumina's Recent Revenue History ($ millions)  
    • Figure 5-8:  Illumina Recent Revenues
    • Table 5-9: Illumina’s Technology Platforms and Targeted Applications  
  • IMMUCOR, INC. 
  • Company Overview 
  • Transfusion Diagnostics  
  • MERIDIAN BIOSCIENCE INC 
  • Company Overview 
    • Figure 5-8:  Meridian Recent Revenues  
  • MESA BIOTECH, INC. (THERMO)  
  • Company Overview 
  • MOLBIO DIAGNOSTICS PVT. LTD. 
  • Company Overview 
  • MYRIAD GENETICS, INC.
  • Company Overview 
  • Financial Review  
    • Table 5-10: Myriad Genetics' Recent Revenue History ($ millions) 
  • NANOSTRING TECHNOLOGIES, INC.  
  • Company Overview 
  • NEUROMODX 
  • Company Overview 
  • OXFORD NANOPORE TECHNOLOGIES LTD  
  • Company Overview 
  • PERKINELMER INC. 
  • Company Overview 
  • PRESCIENT MEDICINE HOLDINGS (AUTOGENOMICS) 
  • Company Overview 
  • PROMEGA CORPORATION  
  • Company Overview 
  • QIAGEN
  • Company Overview 
  • Thermo Fisher Purchase  
    • Table 5-11: Complementary diagnostic products offered by Thermo Fisher, Qiagen 
    • Table 5-12: QIAGEN's Recent Revenue History ($ millions)
  • QUANTUMDX GROUP. 
  • Company Overview 
  • QUIDEL CORPORATION  
  • Company Overview 
  • RHEONIX, INC. 
  • Company Overview 
  • Products  
  • ROCHE DIAGNOSTICS
  • Company Overview 
  • COVID-19 Early Actions 
  • Financial Review  
    • Figure 5-8: Roche Recent Revenue  
    • Table 5-13: Roche Diagnostics' Recent Revenue History ($M)
  • Recent Regulatory and Product Developments 
  • Cobas Liat System - POC  
  • Acquisition of GenMark Diagnostics 
  • Sysmex Agreement  
  • Non-Exclusive 15-Year Collaboration With Illumina 
  • Approval for cobas EZH2 Mutation Test 
  • June 2020 - partnership with SpeeDX 
  • Stratos Genomics
  • HPV 
  • PLUS Cytoogy  
  • ASPiRATION study 
  • Cobas Zika test for blood screening
  • FDA approval of Babesia test  
  • Release of NAVIFY Guidelines app  
  • EBV and BKV Tests on the cobas 6800/8800 Systems 
  • Expanded use of VENTANA PD-L1 (SP142) Assay in triple-negative breast cancer (TNBC) 
  • FDA 510(k) clearance for cobas TV/MG test 
  • SEEGENE 
  • Company Overview 
  • SEKISUI DIAGNOSTICS LLC  
  • Company Overview 
  • SHERLOCK BIOSCIENCES 
  • Company Overview 
  • T2 BIOSYSTEMS 
  • Company Overview 
  • THERMO FISHER SCIENTIFIC INC. 
  • Company Overview 
    • Table 5-14: Thermo Fisher's Recent Revenue History ($ millions)  
  • Transplant Diagnostics
  • qPCR 
  • Sequencing  
  • Qiagen Acquisition Scrapped  
  • VELA DIAGNOSTICS 
  • Company Overview 
  • VERACYTE, INC.
  • Company Overview 
Note: Product cover images may vary from those shown

Loading
LOADING...

  • Abbott Diagnostics 
  • Advanced Cell Diagnostics (Biotechne)
  • Agena Bioscience 
  • Agendia Bv 
  • Agilent Technologies (Incl. Dako) 
  • Aidian Oy  
  • Altona Diagnostics 
  • Amoy Diagnostics 
  • Arup Laboratories 
  • Asuragen Inc. (Bio-Techne) 
  • Bd Interventional
  • Bd Life Sciences 
  • Bd Medical
  • Becton, Dickinson & Co. (BD)
  • Beijing Genomics Institute (Bgi)
  • Berry Genomics 
  • Binx Health
  • Bio-Rad Laboratories, Inc.
  • Biocartis 
  • Biodesix
  • Biomeme, Inc 
  • bioMérieux
  • Bioneer 
  • C. R. Bard, Inc. 
  • Caredx, Inc.  
  • Carefusion Corporation  
  • Credo Bioscience 
  • Ctk Biotech  
  • Danaher (Cepheid and Leica Biosystems)
  • Diasorin 
  • Eiken Chemical  
  • Exact Sciences Corp.  
  • Fluidigm Corporation 
  • Genmark Diagnostics (Roche) 
  • Genotypic Technology Pvt. Ltd.
  • Greiner Bio-One GmbH  
  • Grifols, S. A  
  • Hologic, Inc. 
  • Illumina, Inc.
  • Immucor, Inc. 
  • Meridian Bioscience Inc 
  • Mesa Biotech, Inc. (Thermo)  
  • Molbio Diagnostics Pvt. Ltd. 
  • Myriad Genetics, Inc.
  • Nanostring Technologies, Inc.  
  • Neuromodx 
  • Oxford Nanopore Technologies Ltd  
  • Perkinelmer Inc. 
  • Prescient Medicine Holdings (Autogenomics) 
  • Promega Corporation  
  • Qiagen
  • QIAGEN N.V.
  • Quantumdx Group. 
  • Quidel Corporation  
  • Recent Acquisitions 
  • Rheonix, Inc. 
  • Roche Diagnostics
  • Seegene 
  • Sekisui Diagnostics LLC  
  • Sherlock Biosciences 
  • T2 Biosystems 
  • Thermo Fisher Scientific Inc.
  • Tva Medical, Inc. 
  • Vela Diagnostics 
  • Veracyte, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll